CD55 expression patterns on intestinal neuronal tissue are divergent from the brain

Gut

Volumn 53, Issue 4, 2004, Pages 507-513

  Gelderman, K A ^a   Zijlmans, H J M A A ^a   Vonk, M J ^a   Gorter, A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3D; COMPLEMENTARY DNA; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; RNA;

ANTIGEN EXPRESSION; ARTICLE; BRAIN; CELL TYPE; COLORECTAL CANCER; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTESTINE INNERVATION; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NERVE CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA IN SITU HYBRIDIZATION;

ANTIGENS, CD55; ANTIGENS, CD59; BRAIN; COLON; COMPLEMENT ACTIVATION; COMPLEMENT C3; ELASTIC TISSUE; GENE EXPRESSION; HUMANS; NEUROGLIA; NEURONS; RNA, MESSENGER; SUBMUCOUS PLEXUS;

EID: 1642338116     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.026773     Document Type: Article

References (34)

1. Sharkey KA, Kroese AB. Consequences of intestinal inflammation on the enteric nervous system: neuronal activation induced by inflammatory mediators. Anat Rec 2001;262:79-90.
2. Wood JD, Alpers DH, Andrews PL. Fundamentals of neurogastroenterology. Gut 1999;45(suppl 2):II6-16.
3. Timmermans JP, Hens J, Adriaensen D. Outer submucous plexus: an intrinsic nerve network involved in both secretory and motility processes in the intestine of large mammals and humans. Anat Rec 2001;262:71-8.
4. Gershon MD, Rothman TP. Enteric glia. Glia 1991;4:195-204.
5. Cornet A, Savidge TC, Cabarrocas J, et al. Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A 2001;98:13306-11.
6. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996;111:1683-99.
7. MacDonald TT. Depletion of the enteric nervous system by gene targeting results in haemorrhagic necrosis of the ileum. Gut 1998;43:742-3.
8. Teixeira MM, Gazzinelli RT, Silva JS. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 2002;18:262-5.
9. Zimmermann-Nielsen E, Baatrup G, Thorlacius-Ussing O, et al. Complement activation mediated by mannan-binding lectin in plasma from healthy individuals and from patients with SLE, Crohn's disease and colorectal cancer. Suppressed activation by SLE plasma. Scand J Immunol 2002;55:105-10.
10. Laufer J, Oren R, Goldberg I, et al. Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn's disease. Clin Exp Immunol 2000;120:30-7.
11. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999;20:576-82.
12. Nicholson-Weller A, Wang C. Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994;123:485-91.
13. Seya T, Turner JR, Atkinson JP. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for deavage of C3b and C4b. J Exp Med 1986;163:837-55.
14. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990;71:1-9.
15. Singhrao SK, Neal JW, Rushmere NK, et al. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest 1999;79:1247-59.
16. Asghar SS. Membrane regulators of complement activation and their aberrant expression in disease. Lab Invest 1995;72:254-71.
17. Singhrao SK, Neal JW, Rushmere NK, et al. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000;157:905-18.
18. Gelderman KA, Blok VT, Fleuren GJ, et al. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002;82:483-93.
19. Ruiter DJ, Ferrier CM, Van Muijen GNP, et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. Eur J Cancer 1998;34:1334-40.
20. De Boer WI, Sont JK, van Schadewijk A, et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000;190:619-26.
21. Gasque P, Thomas A, Fontaine M, et al. Complement activation on human neuroblastoma cell lines in vitro: Route of activation and expression of functional complement regulatory proteins. J Neuroimmunol 1996;66:29-40.
22. Morgan BP, Gasque P. Expression of complement in the brain: Role in health and disease. Immunol Today 1996;17:461-6.
23. Koski CL, Estep AE, Sawant-Mane S, et al. Complement regulatory molecules on human myelin and glial cells: Differential expression affects the deposition of activated complement proteins. J Neurochem 1996;66:303-12.
24. Yang C, Jones JL, Barnum SR. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J Neuroimmunol 1993;47:123-32.
25. Gasque P, Morgan BP. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology 1996;89:338-47.
26. Scolding NJ, Morgan BP, Compston DAS. The expression of complement regulatory proteins by adult human oligodendrocytes. J Neuroimmunol 1998;84:69-75.
27. Chen SH, Caragine T, Cheung NKV, et al. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. Am J Pathol 2000;156:1085-91.
28. Werth VP, Ivanov IE, Nussenzweig V. Decay-accelerating factor in human skin is associated with elastic fibers. J Invest Dermatol 1988;91:511-16.
29. Werth VP, Shi X, Kalathil E, et al. Elastic fiber-associated proteins of skin in development and photoaging. Photochem Photobiol 1996;63:308-13.
30. Liberti EA, Gaspar LP, de Carvalho CA, et al. A morpho-quantitative study of the myenteric ganglia throughout the human digestive tract. Rev Hosp Clin Fac Med Sao Paulo 1998;53:55-60.
31. Sayama K, Shiraishi S, Shirakata Y, et al. Characterization of decay-accelerating factor (DAF) in human skin. J Invest Dermatol 1991;96:61-4.
32. Yang LB, Li R, Meri S, et al. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci 2000;20:7505-9.
33. Schmitt CA, Schwaeble W, Wittig BM, et al. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur J Cancer [A] 1999;35:117-124.
34. Li L, Spendlove I, Morgan J, et al. CD55 is over-expressed in the tumour environment. Br J Cancer 2001;84:80-6.